相关实验视频
Updated: Jul 16, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.7K
在体育药物测试中的胰岛素模拟
Andreas Thomas1, Sophia Krombholz1, Johanna Breuer1
1Institute of Biochemistry/Center for Preventive Doping Research, German Sport University Cologne, Cologne, Germany.
Drug testing and analysis
|September 11, 2023
概括
研究人员开发了一种检测胰岛素模拟的新方法,这些潜在的兴奋剂尚未列入WADA禁止清单. 这种测试通过在运动员血中识别这些新型增强性能的物质来增强体育药物测试.
科学领域:
- 运动科学 运动科学 运动科学
- 分析化学 分析化学
- 生物化学 生物化学
背景情况:
- 由于胰岛素及其类型的代谢作用,在运动中禁止使用胰岛素及其类型.
- 新型胰岛素模拟性 (SIRM) 可以激活胰岛素受体,是潜在的性能增强剂.
- 这些SIRM在世界反兴奋剂机构 (WADA) 的禁用清单中没有明确列出.
研究的目的:
- 开发一种快速,可靠和特定的测定方法,用于检测血中的胰岛素仿真S597和S519.
- 为了验证测试用于常规体育药物测试的测试.
- 为了研究这些的体外代谢,并确定降解产物.
主要方法:
- 先进的固体相提取 (SPE) 用于样品制备.
- 液体染色学与高分辨率联质谱学 (LC-HRMS/MS) 结合用于检测.
- 在体外代谢实验以确定代谢产品.
主要成果:
- 成功开发了一种具有0.5 ng/mL检测极限的敏感试验.
- 该试验证明了其适用于常规的体育药物测试.
- 鉴定出了几个目标的代谢降解产物.
结论:
- 开发的LC-HRMS/MS试验有效检测血中的新型胰岛素模拟性.
- 这种方法可以通过识别新兴的性能增强剂来加强反兴奋剂工作.
- 了解代谢有助于对兴奋剂控制样本的分析.
相关概念视频
Glucagon-like Receptor Agonists
357
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
357
Insulin: Biosynthesis, Chemistry, and Preparation
422
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
422
Dipeptidyl Peptidase 4 Inhibitors
211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211
Oral Hypoglycemic Agents: Glinides
183
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
183
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Insulin Formulations: Types and Delivery
225
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
225

